22/120
0.9 / 5 stars
All 120 Win/Lose results shown below
ATRA Roast Me summary
Atara Biotherapeutics, Inc. (ATRA). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinATRA / S&P 142.71% / 15.20% |
LoseATRA / S&P -96.72% / 15.00% |
LoseATRA / S&P -286.96% / 50.40% |
| 2026-Q10/3 |
LoseATRA / S&P -73.85% / -4.33% |
LoseATRA / S&P -88.41% / 11.30% |
LoseATRA / S&P ATRA unavailable / 27.70% |
| 2025-Q41/3 |
WinATRA / S&P 26.24% / 2.65% |
LoseATRA / S&P -6.33% / 9.00% |
LoseATRA / S&P ATRA unavailable / 13.40% |
| 2025-Q32/3 |
WinATRA / S&P 85.62% / 8.12% |
WinATRA / S&P 51.27% / 4.61% |
LoseATRA / S&P ATRA unavailable / 13.45% |
| 2025-Q22/3 |
WinATRA / S&P 29.97% / 10.94% |
WinATRA / S&P 202.41% / 4.83% |
LoseATRA / S&P ATRA unavailable / 10.63% |
| 2025-Q11/3 |
LoseATRA / S&P -55.37% / -4.27% |
WinATRA / S&P 475.53% / 4.98% |
LoseATRA / S&P ATRA unavailable / 10.57% |
| 2024-Q42/3 |
WinATRA / S&P 63.71% / 2.41% |
WinATRA / S&P 1404.02% / 5.25% |
LoseATRA / S&P ATRA unavailable / 6.15% |
| 2024-Q31/3 |
LoseATRA / S&P -4.35% / 5.89% |
WinATRA / S&P 2111.34% / 5.89% |
LoseATRA / S&P ATRA unavailable / 6.11% |
| 2024-Q21/3 |
LoseATRA / S&P -51.01% / 4.28% |
WinATRA / S&P 809.03% / 5.38% |
LoseATRA / S&P ATRA unavailable / 5.12% |
| 2024-Q11/3 |
WinATRA / S&P 35.28% / 10.56% |
LoseATRA / S&P -39.63% / 5.71% |
LoseATRA / S&P ATRA unavailable / 5.59% |
| 2023-Q40/3 |
LoseATRA / S&P -65.34% / 11.69% |
LoseATRA / S&P -86.51% / 6.81% |
LoseATRA / S&P ATRA unavailable / 7.78% |
| 2023-Q30/3 |
LoseATRA / S&P -8.07% / -3.27% |
LoseATRA / S&P ATRA unavailable / 7.52% |
LoseATRA / S&P ATRA unavailable / -5.03% |
| 2023-Q20/3 |
LoseATRA / S&P -44.48% / 8.74% |
LoseATRA / S&P ATRA unavailable / 9.50% |
LoseATRA / S&P ATRA unavailable / -8.57% |
| 2023-Q10/3 |
LoseATRA / S&P -11.59% / 7.50% |
LoseATRA / S&P ATRA unavailable / 10.77% |
LoseATRA / S&P ATRA unavailable / -15.69% |
| 2022-Q40/3 |
LoseATRA / S&P -13.23% / 7.56% |
LoseATRA / S&P ATRA unavailable / 11.88% |
LoseATRA / S&P ATRA unavailable / -17.99% |
| 2022-Q30/3 |
LoseATRA / S&P -51.48% / -4.88% |
LoseATRA / S&P ATRA unavailable / 13.47% |
LoseATRA / S&P ATRA unavailable / -1.41% |
| 2022-Q20/3 |
LoseATRA / S&P -16.15% / -16.10% |
LoseATRA / S&P ATRA unavailable / 13.71% |
LoseATRA / S&P ATRA unavailable / 11.04% |
| 2022-Q10/3 |
LoseATRA / S&P -41.05% / -4.60% |
LoseATRA / S&P ATRA unavailable / 15.97% |
LoseATRA / S&P ATRA unavailable / 42.23% |
| 2021-Q40/3 |
LoseATRA / S&P -11.96% / 11.03% |
LoseATRA / S&P ATRA unavailable / 15.00% |
LoseATRA / S&P ATRA unavailable / 96.40% |
| 2021-Q31/3 |
WinATRA / S&P 15.11% / 0.58% |
LoseATRA / S&P ATRA unavailable / 10.77% |
LoseATRA / S&P ATRA unavailable / 69.42% |
| 2021-Q20/3 |
LoseATRA / S&P 8.29% / 8.55% |
LoseATRA / S&P ATRA unavailable / 6.58% |
LoseATRA / S&P ATRA unavailable / 51.81% |
| 2021-Q10/3 |
LoseATRA / S&P -26.85% / 6.17% |
LoseATRA / S&P ATRA unavailable / -1.06% |
LoseATRA / S&P ATRA unavailable / 7.39% |
| 2020-Q41/3 |
WinATRA / S&P 51.47% / 12.15% |
LoseATRA / S&P ATRA unavailable / -3.72% |
LoseATRA / S&P ATRA unavailable / -33.42% |
| 2020-Q30/3 |
LoseATRA / S&P -11.05% / 8.93% |
LoseATRA / S&P ATRA unavailable / -2.04% |
LoseATRA / S&P ATRA unavailable / -27.10% |
| 2020-Q21/3 |
WinATRA / S&P 71.21% / 20.54% |
LoseATRA / S&P ATRA unavailable / -0.46% |
LoseATRA / S&P ATRA unavailable / -27.11% |
| 2020-Q10/3 |
LoseATRA / S&P -48.33% / -19.60% |
LoseATRA / S&P ATRA unavailable / 3.47% |
LoseATRA / S&P ATRA unavailable / -14.75% |
| 2019-Q41/3 |
WinATRA / S&P 16.64% / 9.07% |
LoseATRA / S&P ATRA unavailable / 5.36% |
LoseATRA / S&P ATRA unavailable / 2.99% |
| 2019-Q30/3 |
LoseATRA / S&P -29.79% / 1.70% |
LoseATRA / S&P ATRA unavailable / 5.02% |
LoseATRA / S&P ATRA unavailable / 0.21% |
| 2019-Q20/3 |
LoseATRA / S&P -49.41% / 4.30% |
LoseATRA / S&P ATRA unavailable / 6.64% |
LoseATRA / S&P ATRA unavailable / 8.65% |
| 2019-Q11/3 |
WinATRA / S&P 14.42% / 13.65% |
LoseATRA / S&P ATRA unavailable / 8.12% |
LoseATRA / S&P ATRA unavailable / 14.29% |
| 2018-Q40/3 |
LoseATRA / S&P -15.99% / -13.52% |
LoseATRA / S&P ATRA unavailable / 9.05% |
LoseATRA / S&P ATRA unavailable / 18.23% |
| 2018-Q31/3 |
WinATRA / S&P 12.52% / 7.71% |
LoseATRA / S&P ATRA unavailable / 10.21% |
LoseATRA / S&P ATRA unavailable / 19.06% |
| 2018-Q20/3 |
LoseATRA / S&P -5.77% / 3.43% |
LoseATRA / S&P ATRA unavailable / 9.03% |
LoseATRA / S&P ATRA unavailable / 14.46% |
| 2018-Q11/3 |
WinATRA / S&P 115.47% / -0.76% |
LoseATRA / S&P ATRA unavailable / 7.68% |
LoseATRA / S&P ATRA unavailable / 12.46% |
| 2017-Q41/3 |
WinATRA / S&P 9.37% / 6.64% |
LoseATRA / S&P ATRA unavailable / 7.03% |
LoseATRA / S&P ATRA unavailable / 13.82% |
| 2017-Q31/3 |
WinATRA / S&P 18.21% / 4.48% |
LoseATRA / S&P ATRA unavailable / 5.68% |
LoseATRA / S&P ATRA unavailable / 17.57% |
| 2017-Q20/3 |
LoseATRA / S&P -31.87% / 3.09% |
LoseATRA / S&P ATRA unavailable / 4.83% |
LoseATRA / S&P ATRA unavailable / 17.74% |
| 2017-Q11/3 |
WinATRA / S&P 44.72% / 6.07% |
LoseATRA / S&P ATRA unavailable / 3.67% |
LoseATRA / S&P ATRA unavailable / 13.32% |
| 2016-Q40/3 |
LoseATRA / S&P -33.61% / 3.82% |
LoseATRA / S&P ATRA unavailable / 2.09% |
LoseATRA / S&P ATRA unavailable / 7.05% |
| 2016-Q30/3 |
LoseATRA / S&P -4.98% / 3.85% |
LoseATRA / S&P ATRA unavailable / 0.20% |
LoseATRA / S&P ATRA unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | ATRA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -23.94% | 20.78% |
| Annualized return | -23.94% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | ATRA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -97.66% | 83.14% |
| Annualized return | -52.82% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | ATRA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -98.15% | 319.30% |
| Annualized return | -32.91% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |